As a mechanism to disrupt tumor hypoxia, the hypoxia-activated prodrug TH-302 also demonstrated pre-clinical benefits in improving immunotherapy efficiency by promoting CD8+ T-cell effector function and diminishing MDSCs (47). This evidence concerns the gene CD8A and neoplasm.